Heron Therapeutics is trading at $0.39, down 5.10%, with no clear company-specific catalyst identified at 10:26 a.m. ET on October 12, 2026.
- Heron’s official news page lists its second-quarter results on October 8 as its latest release, with no new announcement for October 12.
- Broader markets were nearly flat, while available biotech-market data showed XBI down 0.4%; neither establishes a clear cause for the stock’s decline.